4Hu O Y, Pan C Y, Yu J M, et al. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey [J]. Eur Heart J, 2006,27(21):2573-2579.
5Hoffmann IS, Alfieri A B, Cubeddu L X. Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salT -sensitive Hispanics [J]. J Hum Hypertens, 2007,21 (7):571-578.
6Kalogeropulos A, Georgiopulou V, Harris T B, et al. Gliycemic stayus and incident hear failure in elderly without history of diabetes mellitus: the health, aging, and body com-position study [J ]. J Card Fail, 2009,15 (7): 593-599.
7Holman R R, Paul S K, Bethel M A, et al. 10-year follow-up of intensive glucose control in type 2 diabetes [J]. N Engl J Med, 2008,359(15):1577-1589.
8McAlister FA, Eurich 0 T, Majumdar S R, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy [J]. Eur J Heart Fail, 2008, 10 (7): 703-708.
9Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral anti diabetes drugs: retrospective cohort study using UK general practice research database [J ]. BMJ, 2009,339: b4731.
10Pantalone K M, Kattan M W, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonyIureas , a retrospective analysis [J]. Acta Diabetol, 2009, 46(2): 145-154.
